Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Bulletin from extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ)

Notice of extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ)

First patient enrolled in pivotal clinical phase 3 study NEFIGARD with lead candidate Nefecon

Calliditas Therapeutics to present and attend investor conferences in November 2018

Interim Report Q3, 2018

Calliditas Therapeutics to host conference call to provide Q3 2018 Business Update

Calliditas Therapeutics’ nomination committee for the AGM 2019

Presentation at International IgA Nephropathy Network meeting highlighting supportive post-hoc analysis of the NEFIGAN study

Post-hoc results from NEFIGAN study to be presented at the International IgA Nephropathy Network meeting (IIgANN)

Interim Report Q2, 2018

Calliditas Therapeutics to host conference call to provide Q2 2018 Business Update

The 15th International Symposium on IgA nephropathy accepts Calliditas Therapeutics abstracts

Calliditas Therapeutics selected to present at the 25th Annual NewsMakers in the Biotech Industry

Number of shares and votes in Calliditas Therapeutics

Exercise of over-allotment option and end of the stabilization period

Stabilization notice

Number of shares and votes in Calliditas Therapeutics

Trading in Calliditas’ share commences today on Nasdaq Stockholm

Calliditas announces listing on Nasdaq Stockholm and related prospectus

Surrogate marker and design of Calliditas Therapeutics’ IgA nephropathy Phase 3 study agreed with the FDA

Pharmalink is renamed Calliditas Therapeutics

Thomas Eklund New Chairman of Pharmalink

Pharmalink strengthens its management team. Appoints new Chief Financial Officer and head of communications

Positive Phase 2b Trial of Pharmalink’s Nefecon in Primary IgA Nephropathy presented at Leading Kidney Disease Conference

Positive Phase 2b Trial of Pharmalink’s Nefecon in IgA Nephropathy Selected for Presentation at Leading Kidney Disease Conference

Pharmalink AB announces the appointment of a new Chief Executive Officer

Positive results of Phase 2b Clinical Trial of Pharmalink’s Nefecon in Primary IgA Nephropathy published in The Lancet

Pharmalink strengthens team in preparation for Phase III trials with Nefecon in IgA Nephropathy, a progressive inflammatory kidney disease

Pharmalink announces European orphan drug designation for Nefecon® for treatment of IgA Nephropathy, an inflammatory kidney disease

Pharmalink announces positive result in Phase 2b Trial of Nefecon®

Pharmalink announces an open Investigational New Drug (IND) application for Nefecon®

Data from clinical study of Pharmalink’s Nefecon® to be presented at American Society of Nephrology’s Kidney Week 2014

Pharmalink extends patent protection for Nefecon® treatment for renal disease

Pharmalink’s core patents for Nefecon® treatment for renal disease granted in United States, Europe, China and Hong Kong

Pharmalink completes enrolment of patients into Phase IIB clinical study (NEFIGAN) of Nefecon®

Pharmalink initiates a pivotal Phase IIb trial with Nefecon® in patients with primary IgA nephropathy

Pharmalink enters manufacturing agreement for Nefecon®

Pharmalink AB Receives US Orphan Drug Designation for Nefecon® (PL-56)

Grifols agrees to acquire intellectual property for treatment of post-polio syndrome from Pharmalink AB

Pharmalink AB receives patent for Nefecon® principle. Japanese grant supports Asian partnering program.

Pharmalink AB completes Phase II clinical study with renal disease drug Nefecon

Pharmalink reports promising interim results from phase II trials for new renal disease drug Nefecon®